D. E. Shaw & Co. Inc. raised its stake in shares of Amedisys Inc (NASDAQ:AMED) by 20.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 446,941 shares of the health services provider’s stock after buying an additional 76,403 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Amedisys were worth $54,263,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of AMED. William Blair Investment Management LLC grew its holdings in Amedisys by 937.5% during the 2nd quarter. William Blair Investment Management LLC now owns 988,533 shares of the health services provider’s stock valued at $120,018,000 after buying an additional 893,253 shares in the last quarter. Riverbridge Partners LLC purchased a new position in Amedisys during the 2nd quarter valued at about $80,465,000. Eagle Asset Management Inc. purchased a new position in Amedisys during the 2nd quarter valued at about $35,359,000. Carillon Tower Advisers Inc. purchased a new position in Amedisys during the 2nd quarter valued at about $23,250,000. Finally, Marshall Wace LLP grew its holdings in Amedisys by 289.2% during the 1st quarter. Marshall Wace LLP now owns 220,503 shares of the health services provider’s stock valued at $27,180,000 after buying an additional 163,842 shares in the last quarter. 88.53% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the company. Royal Bank of Canada lifted their target price on Amedisys to $150.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. ValuEngine raised Amedisys from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. Raymond James boosted their price objective on Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday, July 15th. Finally, Barclays boosted their price objective on Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday, August 5th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Amedisys presently has a consensus rating of “Buy” and a consensus price target of $138.59.
In related news, CFO Scott G. Ginn sold 4,871 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $132.06, for a total value of $643,264.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Paul North sold 1,183 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $130.00, for a total value of $153,790.00. The disclosure for this sale can be found here. Insiders have sold 22,749 shares of company stock valued at $2,986,811 in the last three months. 2.90% of the stock is owned by insiders.
Shares of NASDAQ AMED traded up $3.34 during midday trading on Friday, hitting $135.43. 301,078 shares of the company’s stock were exchanged, compared to its average volume of 236,980. Amedisys Inc has a 12-month low of $97.38 and a 12-month high of $141.98. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 0.58. The company has a market cap of $4.25 billion, a price-to-earnings ratio of 37.31, a PEG ratio of 1.97 and a beta of 1.46. The business’s fifty day moving average price is $132.39 and its two-hundred day moving average price is $123.81.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 31st. The health services provider reported $1.21 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.24. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The company had revenue of $492.98 million during the quarter, compared to analyst estimates of $489.66 million. During the same quarter in the previous year, the firm earned $1.00 earnings per share. Amedisys’s revenue was up 19.8% on a year-over-year basis. Equities analysts expect that Amedisys Inc will post 4.13 earnings per share for the current fiscal year.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Recommended Story: Municipal Bonds
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.